COMPASS Pathways plc (NASDAQ:CMPS) Short Interest Update

COMPASS Pathways plc (NASDAQ:CMPS) saw a large drop in short interest during the month of July. As of July 31st, there was short interest totalling 3,850,000 shares, a drop of 11.9% from the July 15th total of 4,370,000 shares. Based on an average daily volume of 415,500 shares, the days-to-cover ratio is currently 9.3 days.

Hedge Funds Weigh In On COMPASS Pathways

Several institutional investors have recently added to or reduced their stakes in the business. Quest Partners LLC acquired a new stake in COMPASS Pathways during the fourth quarter worth about $33,000. Mirae Asset Global Investments Co. Ltd. increased its stake in COMPASS Pathways by 4.7% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 110,939 shares of the company’s stock worth $971,000 after acquiring an additional 4,981 shares during the last quarter. Tidal Investments LLC increased its stake in COMPASS Pathways by 43.6% during the first quarter. Tidal Investments LLC now owns 19,082 shares of the company’s stock worth $159,000 after acquiring an additional 5,795 shares during the last quarter. AdvisorShares Investments LLC increased its stake in COMPASS Pathways by 13.5% during the second quarter. AdvisorShares Investments LLC now owns 60,882 shares of the company’s stock worth $362,000 after acquiring an additional 7,243 shares during the last quarter. Finally, Conservest Capital Advisors Inc. acquired a new stake in COMPASS Pathways during the fourth quarter worth about $91,000. 46.19% of the stock is currently owned by institutional investors and hedge funds.

COMPASS Pathways Trading Up 1.0 %

COMPASS Pathways stock traded up $0.07 during trading on Monday, hitting $7.05. The company’s stock had a trading volume of 240,400 shares, compared to its average volume of 546,294. The stock has a market capitalization of $482.09 million, a price-to-earnings ratio of -2.97 and a beta of 2.27. The stock’s fifty day moving average is $6.82 and its 200 day moving average is $8.35. COMPASS Pathways has a 1-year low of $5.01 and a 1-year high of $12.75. The company has a debt-to-equity ratio of 0.12, a quick ratio of 15.23 and a current ratio of 15.23.

COMPASS Pathways (NASDAQ:CMPS) last released its earnings results on Thursday, August 1st. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.03). During the same quarter in the previous year, the business posted ($0.62) earnings per share. As a group, equities research analysts predict that COMPASS Pathways will post -2.24 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on CMPS shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of COMPASS Pathways in a research note on Friday, June 21st. Royal Bank of Canada initiated coverage on COMPASS Pathways in a research report on Tuesday, July 23rd. They set an “outperform” rating and a $23.00 target price on the stock. Canaccord Genuity Group cut their price target on COMPASS Pathways from $50.00 to $48.00 and set a “buy” rating for the company in a report on Friday, August 2nd. Finally, HC Wainwright reissued a “buy” rating and issued a $120.00 price target on shares of COMPASS Pathways in a report on Wednesday, July 31st. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $47.40.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.